Personalised and Precision Medicine in Cancer Clinical Trials: Panacea for Progress or Pandora's Box?

Publisher： Karger

E-ISSN： 1662-8063|18|6|329-337

ISSN： 1662-4246

Source： Public Health Genomics, Vol.18, Iss.6, 2015-0, pp. : 329-337

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Getting Personal: Accelerating Personalised and Precision Medicine Integration into Clinical Cancer Research and Care in Clinical Trials

By  

Public Health Genomics, Vol. 18, Iss. 6, 2015-0 ,pp. : 325-328

Karger

Access to resources Recommend Favorite

Clinical Next Generation Sequencing for Precision Medicine in Cancer

By  

Current Genomics, Vol. 16, Iss. 4, 2015-06 ,pp. : 253-263

Bentham Science Publishers

Access to resources Recommend Favorite

Cancer Precision Medicine: Why More Is More and DNA Is Not Enough

By  

Public Health Genomics, Vol. 20, Iss. 2, 2017-06 ,pp. : 70-80

Karger

Access to resources Recommend Favorite

An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe

By  

Public Health Genomics, Vol. 17, Iss. 5-6, 2014-11 ,pp. : 287-298

Karger

Access to resources Recommend Favorite

Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care

By  

Public Health Genomics, Vol. 18, Iss. 6, 2015-0 ,pp. : 349-358

Karger

Access to resources Recommend Favorite